Physician

Amitabha Mazumder, M.D.

According to 2025 Medicare claims, Amitabha Mazumder, M.D. (NPI: 1881682318) practices medical oncology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is THE ONCOLOGY INSTITUTE CA, A PROFESSIONAL CORPORATION (NPI: 1275651515; TIN: 20-8366709) and primary practice location at 91204-2570. Mazumder is affiliated with the APA ACO Inc. (ACO ID: D0215), participating under the REACH model.

Mazumder's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 114 traditional Medicare patients, billed 16,220 HCPCS/CPT codes, and received $452,299 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,500 prescription claims across 250 beneficiaries totaling $4,923,244 in drug costs, led by Verzenio (Abemaciclib). DME data shows 15 claims. Open Payments data shows 233 records totaling $737,458. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $29,808 to $452,299. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,432,147 to $4,923,244. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	165	659	$29,808
2016	112	3,747	$45,006
2017	151	3,903	$106,471
2018	141	10,426	$119,303
2019	145	11,901	$120,438
2020	90	2,072	$21,146
2021	82	998	$31,155
2022	81	6,406	$101,677
2023	106	8,203	$294,840
2024	114	16,220	$452,299

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	76	554	$1,432,147
2016	32	86	$100,584
2017	23	137	$343,421
2018	88	328	$570,034
2019	149	723	$1,603,088
2020	154	713	$2,289,589
2021	169	865	$3,610,566
2022	198	972	$3,160,138
2023	216	1,244	$4,658,259
2024	250	1,500	$4,923,244

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	15	$434

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	11	11	$125
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	82	150	$99
M0010	Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services	16	117	$87
99443	Telephone medical discussion with physician, 21-30 minutes	36	63	$79
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	12	23	$26

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	35	980	$478,744
Xtandi	Enzalutamide	33	990	$448,969
Revlimid	Lenalidomide	27	743	$428,459
Pomalyst	Pomalidomide	22	616	$399,092
Ibrance	Palbociclib	23	644	$370,937

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$434

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	204	$5,998	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	29	$731,461	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amitabha Mazumder, M.D.?

Tedicare shows public-source Medicare data for Amitabha Mazumder, M.D. (NPI 1881682318), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amitabha Mazumder, M.D. have ACO affiliation data?

Amitabha Mazumder, M.D. is shown with ACO affiliation data for APA ACO Inc. (REACH, ACO ID D0215).

What billing organization is linked to Amitabha Mazumder, M.D.?

Amitabha Mazumder, M.D. is linked to THE ONCOLOGY INSTITUTE CA, A PROFESSIONAL CORPORATION (billing NPI 1275651515) in the available physician profile data.

Does Amitabha Mazumder, M.D. have Open Payments data?

Amitabha Mazumder, M.D. has 233 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.